Please join AVAC for updates on the PURPOSE trials for injectable lenacapavir for PrEP. Gilead will provide an overview of the PURPOSE 1 and 2 trial results and insight into the status of PURPOSE 3, 4, and 5. This will be an opportunity for civil society to hear from Gilead directly.
